Hope thrives in the desert
Home > Science & Research > Clinical Trials

Available Clinical Trials

The Nevada Cancer Institute offers many diverse options for the treatment of cancer. For more detailed description of each trial, click on the type of cancer to open a PDF document with the details, including criteria for enrollment, for selected study.

» Phase I
» Genitourinary
» Lung
» Gastrointestinal
» Hematology
» Skin/Melanoma
» Phase IV
» Return to Clinical Trials main

Phase 1

Advanced Solid TumorsPhase ISandy
(702)822-5174		Phase I clinical and Pharmacokinetic study of CBP501 and cicplatin every 3 weeks in patients with advanced refractory solid tumors
Advanced Solid Malignancies Phase I/IIDianna
(702)822-5483		A Phase I/II, multi-center, open label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
Advanced Solid Malignancies Phase ISandy
(702)822-5174		A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer
Refractory or Metastatic Tumors Phase ISandy
(702)822-5174		A Phase I Study of EC0225 Administered Weeks 1 & 2 of a 4 Week Cycle
Advanced Solid Tumors Phase ITherica
(702)822-5293		An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 with AMG 706, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors
Advanced Solid Malignancies Phase I/IIDianna
(702)822-5483		A phase I/II, multi-center, open-label study of BGT226, administered orally in adult patients with advanced solid malignancies including patients with advanced breast cancer
Adult Cancer Patients Phase IDianna
(702)822-5483		A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Advanced Solid Tumors & Malignant Pleural Mesothelioma Phase I/IIDianna
(702)822-5483		Phase I/II study of a triplet combination of CBP501, pemetrexed and cisplatin in patients with advanced solid tumors and in chemotherapy-naïve patients with malignant pleural mesothelioma
Advanced Solid Tumors Phase IIKaren
(702)822-5367		"A Randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors"
top ^

Gastrointestinal

GI cancers Phase I/IIKaren
(702)822-5367		A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combinations with chemotherapy and bevacizumab in patients with metastatic colorectal cancer preceded by a phase 1 portion
top ^

Genitourinary

Prostate Cancer Phase IIICarol
(702)822-5449		A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT by Chemotherapy With Docetaxel and Prednisone For Localized, High-Risk Prostate Cancer
Metastatic Kidney Carcinoma Phase IIJacky
(702)822-5393		Phase II Study of Perifosine for Patients with Metastatic Carcinoma of the Kidney who have Progressed on a VEGF Receptor Inhibitor
Detection of Clear Cell Renal Cell CarcinomaPhase IIIJacky
(702)822-5393		A Comparative Study of PET/CT vs. Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250 (124IcG250)
Prostate Cancer Phase IbJoAnn
(702)822-5149		An open label, single arm, Phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel & prednisone in patients with hormone refractory prostate cancer
Prostate CancerPhase IIICarol
(702)822-5449		A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Prostate Cancer Phase IIIJacky
(702)822-5393		A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Clear Cell Renal Cell Carcinoma Phase IJoAnn
(702)822-5149		A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1411 Administered Every 14 Days in Subjects with Advanced or Recurrent Clear Cell Renal Cell Carcinoma
Bladder Cancer Phase I/IIJacky
(702)822-5393		A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
Prostate Adenocarcinoma Phase IICarol
(702)822-5449		A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy
Metastatic Renal Cell Cancer Phase IIIAnnette
(702)822-5177		Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: Axis Trial
top ^

Hematology

Non-Hodgkin's LymphomaPhase I/IIChristine
(702) 822-5456		A Phase 1/2 Study of CMC-544 Administered in Combination With Rituximab in Subjects With Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's LymphomaPhase I/IIChristine
(702) 822-5456		Phase 1/2 Dose-Escalation Study Of AME 133v (LY2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin’s Lymphoma
Chronic Lymphocytic Leukemia & Non-Hodgkin's Lymphoma Phase I/IIChristine
(702)822-5456		Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS 9219 Administered Once Every Three Weeks Intravenously to Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma Phase IChristine
(702)822-5456		A Phase Ib Study of SGN-40 (anti-huCD40 mAb) in Combination with Rituximab and Gemcitabine for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
top ^

Lung

Non-Small Cell Lung Cancer Phase I/IIAnnette
(702)822-5177		Phase I/II Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy followed by Every 21-day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage III A/B Non-Small Cell Lung Cancer
Non-Small-Cell Lung CancerPhase IIITherica
(702)822-5293		A randomized phase III comparison of standard-dose (60 Gy) versus high dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB Non-Small Cell Lung Cancer
Lung Cancer Phase IIAnnette
(702)822-5177		A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carboplatin) Compared to Taxol®/Paraplatin® Alone in Previously Untreated Subjects with Lung Cancer
top ^

Skin/Melanoma

Melanoma Phase IIAnnette
(702)822-5177		A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage III or Stage IV Melanoma
top ^

Phase IV

Colorectal Cancer, Non-Small Cell Lung Cancer, & Breast Cancer Phase IVJacky
(702)822-5393		An observational study of Avastin (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic Non Small Cell Lung (excluding predominant squamous cell histology), or locally recurrent or metastatic breast cancer
top ^
Contact Us
Please contact us with any questions or comments.
(702) 822-LIFE

(866) 621-NVCI

FightHere.org

Latest News

Nevada Cancer Institute Receives CAP Accreditation

Read more

Nevadans Encouraged to Join Grassroots Movement NVCI launches e-advocacy website “FightHere.Org“

Read more

Maps & Directions

To visit our state-of-the-art, flagship facility click here.

Outreach & Education offices:

Las Vegas | Sparks | Elko | Fallon
©2009 Nevada Cancer Institute. All rights reserved. One Breakthrough Way. Las Vegas, NV 89135 | (702) 822-LIFE
Contact Us | Notice of Privacy Practices | Patient Rights | Site Map | Employees | Home